Physician profile
John W Craddock
NPI 1699752857
$2,983.22
in general payments reported to CMS, 2019-2025
18 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $303 · 2021: $366 · 2022: $435 · 2023: $737 · 2024: $130 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345 · Travel and Lodging: $3.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,344.71 |
| Travel and Lodging | $3.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $628.66 | 2019-2023 | Relieva Spinplus, Trudi Nav Cable, Acclarent Aera |
| Optinose US, INC. | $320.77 | 2019-2021 | |
| Medtronic, INC. | $313.58 | 2023-2025 | Propel, Sinuva |
| Stryker Corporation | $257.33 | 2019-2022 | |
| Intersect Ent, INC. | $250.85 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $208.94 | 2023-2024 | Dupixent |
| Glaxosmithkline, LLC. | $180.24 | 2025 | Nucala |
| Neurent Medical Limited | $164.42 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Aerin Medical INC. | $137.46 | 2019-2020 | |
| Inspire Medical Systems, INC. | $136.81 | 2022 | |
| Genzyme Corporation | $127.22 | 2023 | |
| Olympus America INC. | $115.68 | 2019-2024 | Olympus, Olympus |
| Axogen | $48.08 | 2020 | |
| Integra Lifesciences Corporation | $24.12 | 2025 | Trudi Probe, Inspira Air, Acclarent Aera |
| Regeneron Pharmaceuticals, INC. | $20.01 | 2024 | Dupixent |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $17.39 | 2023 | Ryaltris |
| Kowa Pharmaceuticals America, INC. | $16.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.66 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Craddock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.